• Federal Court Prohibits the Approval of a Generic Prodrug [CELLCEPT® (mycophenolate mofetil)]
  • July 29, 2011 | Authors: Jason Markwell; Graham McNeil
  • Law Firm: Norton Rose Canada LLP - Toronto Office
  • On July 13, 2011, the Federal Court allowed an application by Hoffman La-Roche Limited (“Roche”), pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex Inc. (“Apotex”) in respect of its generic version of the drug mycophenolate mofetil (“MMF”) until after the expiry of Canadian Patent No. 1,333,285 (the “285 Patent”).